Latest period
−$630.00M
YoY change
-37.6%
5Y CAGR
—
Peak year (2021)
$13.62B
Latest annual
−$1.87B
Operating Cash Flow history chart for Moderna (MRNA) from 2016 to 2025
Latest: −$1.87B
Operating Cash Flow growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -37.6%
Operating Cash Flow history table for Moderna (MRNA) from 2016 to 2025
| 2025 | −$1.87B | -37.6% | +$1.13B | ||
| 2024 | −$3.00B | -3.7% | +$114.00M | ||
| 2023 | −$3.12B | -162.6% | −$8.10B | ||
| 2022 | $4.98B | -63.4% | −$8.64B | ||
| 2021 | $13.62B | +571.9% | +$11.59B | ||
| 2020 | $2.03B | -541.6% | +$2.49B | ||
| 2019 | −$458.97M | +38.7% | −$128.10M | ||
| 2018 | −$330.87M | -0.2% | +$619.00K | ||
| 2017 | −$331.48M | -596.7% | −$398.22M | ||
| 2016 | $66.73M | — | — |
- 2025−$1.87B-37.6%
- 2024−$3.00B-3.7%
- 2023−$3.12B-162.6%
- 2022$4.98B-63.4%
- 2021$13.62B+571.9%
- 2020$2.03B-541.6%
- 2019−$458.97M+38.7%
- 2018−$330.87M-0.2%
- 2017−$331.48M-596.7%
- 2016$66.73M—
Operating Cash Flow values are taken from Moderna's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Moderna (MRNA)
Operating Cash Flow for Moderna (MRNA): headline value −$630.00M · YoY -37.6%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Moderna (MRNA) operating cash flow is −$1.87B – plunged 37.6% year-over-year.
Between 2021 and 2025, Moderna operating cash flow plunged 113.8%, falling from $13.62B to −$1.87B.
Across the available history, operating cash flow reached its high of $13.62B in 2021 and its low of −$3.12B in 2023.
Moderna Operating Cash Flow by Year
Moderna Operating Cash Flow 2025: −$1.87B
2025's operating cash flow for Moderna came in at −$1.87B, plunged 37.6% below 2024.
Moderna Operating Cash Flow 2024: −$3.00B
Moderna posted operating cash flow of −$3.00B in 2024, edged down 3.7% below 2023.
Moderna Operating Cash Flow 2023: −$3.12B
In 2023, Moderna reported operating cash flow of −$3.12B, plunged 162.6% below 2022. This figure represents the lowest annual value in the available history.
Moderna Operating Cash Flow 2022: $4.98B
Moderna operating cash flow in 2022 was $4.98B, plunged 63.4% below 2021.
Moderna Operating Cash Flow 2021: $13.62B
Moderna operating cash flow in 2021 was $13.62B.
See more financial history for Moderna (MRNA).
Sector peers by Operating Cash Flow
Healthcare peers of Moderna (MRNA), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation